Contact
searchSearch
HMP Global

HEOR Topic Center

Featured Article

News
Added SGLT2 Inhibitor Therapy of Intermediate/Low Value in Heart Failure With Preserved Ejection Fraction 
03/29/2023
Jolynn Tumolo
Researchers investigated the lifetime cost effectiveness of standard therapy with vs without an SGLT2 inhibitor to reduce the risk of adverse outcomes in patients with heart failure.
Researchers investigated the lifetime cost effectiveness of standard therapy with vs without an SGLT2 inhibitor to reduce the risk of adverse outcomes in patients with heart failure.
Researchers investigated the...
03/29/2023
First Report Managed Care
Headshot of Merle Diamond, MD, Diamond Headache Clinic, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
Migraine's Impact on Productivity, Quality of Life
05/19/2022
Edan Stanley; Maria Asimopoulos
Merle Diamond, MD, AQH, director, Diamond Headache Clinic and inpatient headache unit at Saint Joseph Hospital, offers insight into the prevalence and burden of migraine, as well as risk factors that can cause migraine to progress from...
Merle Diamond, MD, AQH, director, Diamond Headache Clinic and inpatient headache unit at Saint Joseph Hospital, offers insight into the prevalence and burden of migraine, as well as risk factors that can cause migraine to progress from...
Merle Diamond, MD, AQH,...
05/19/2022
First Report Managed Care
Headshot of Gary Owens, MD, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
How Payers Can Use Clinical, Value Comparison Data for Atopic Dermatitis Therapy
09/24/2021
Edan Stanley
Gary Owens, MD, president of Gary Owens Associates, shares his thoughts on the challenges of choosing treatment options for patients with atopic dermatitis, and highlights key takeaways for payers from a recent ICER report which compared the...
Gary Owens, MD, president of Gary Owens Associates, shares his thoughts on the challenges of choosing treatment options for patients with atopic dermatitis, and highlights key takeaways for payers from a recent ICER report which compared the...
Gary Owens, MD, president of...
09/24/2021
First Report Managed Care
News
Screening for Spinal Muscular Atrophy Enhances Nusinersen Cost-Effectiveness
01/22/2021
“Universal newborn screening for spinal muscular atrophy provides improved economic value for payers and patients when nusinersen is available,” wrote researchers from Weill Cornell Medical College and the University of Utah School of...
“Universal newborn screening for spinal muscular atrophy provides improved economic value for payers and patients when nusinersen is available,” wrote researchers from Weill Cornell Medical College and the University of Utah School of...
“Universal newborn screening for...
01/22/2021
First Report Managed Care
News
Cost-Effectiveness of Implantable Loop Recorder Monitoring After Stroke in Line Wth Other Therapies
12/06/2020
For detecting occult atrial fibrillation in patients with cryptogenic stroke, 3-year implantable loop recorder monitoring has a cost per quality-adjusted life-year gained in the range of other publicly funded therapies
For detecting occult atrial fibrillation in patients with cryptogenic stroke, 3-year implantable loop recorder monitoring has a cost per quality-adjusted life-year gained in the range of other publicly funded therapies
For detecting occult atrial...
12/06/2020
First Report Managed Care
Videos
Discussing Treatment Paradigm Shifts, Successful Therapy Options for Atopic Dermatitis
11/13/2020
Vivian Shi, MD, FAAD, associate professor of dermatology, University of Arkansas for Medical Sciences, describes challenges involved with treating atopic dermatitis, highlights the benefits of dupilumab—particularly among pediatric patients,...
Vivian Shi, MD, FAAD, associate professor of dermatology, University of Arkansas for Medical Sciences, describes challenges involved with treating atopic dermatitis, highlights the benefits of dupilumab—particularly among pediatric patients,...
Vivian Shi, MD, FAAD, associate...
11/13/2020
First Report Managed Care
Literature Review
Regulating the Use of CAR-T Therapy Outside of the Drug Paradigm
10/23/2020
Julie Gould
Currently, chimeric antigen receptor T-cell (CAR-T) therapies are regulated as drugs—often leading to higher prices and barriers to access for patients, as well as financial strains for hospitals. However, in a recent insights article in JAMA...
Currently, chimeric antigen receptor T-cell (CAR-T) therapies are regulated as drugs—often leading to higher prices and barriers to access for patients, as well as financial strains for hospitals. However, in a recent insights article in JAMA...
Currently, chimeric antigen...
10/23/2020
First Report Managed Care
Podcasts
Weighing Benefits and Challenges to Effectively Treat Atopic Dermatitis
09/16/2020
Steven Feldman, MD, PhD, Wake Forest University School of Medicine, discusses the real-world effectiveness of dupilumab for the treatment of atopic dermatitis, how this data is relevant for payers, and stresses the importance of studying...
Steven Feldman, MD, PhD, Wake Forest University School of Medicine, discusses the real-world effectiveness of dupilumab for the treatment of atopic dermatitis, how this data is relevant for payers, and stresses the importance of studying...
Steven Feldman, MD, PhD, Wake...
09/16/2020
First Report Managed Care
First Report
HEOR First Report: A Deeper Look at the Benefits of Hemlibra
08/31/2020
Edan Stanley
Karen Powell, PharmD, MS, Pharmacy Solutions Coordinator, Conduent, discusses a recent study in which she and her colleagues measured the cost effectiveness and utilizations rates associated with emicizumab-kxwh treatment for patients with...
Karen Powell, PharmD, MS, Pharmacy Solutions Coordinator, Conduent, discusses a recent study in which she and her colleagues measured the cost effectiveness and utilizations rates associated with emicizumab-kxwh treatment for patients with...
Karen Powell, PharmD, MS,...
08/31/2020
First Report Managed Care
News
Examining the Cost-Effectiveness of DLBCL Treatment
08/27/2020
Because patients with relapsed or refractory diffuse large B-cell lymphoma have limited treatment options and poor prognoses, researchers recently examined the cost-effectiveness of treatments for this patient population.
Because patients with relapsed or refractory diffuse large B-cell lymphoma have limited treatment options and poor prognoses, researchers recently examined the cost-effectiveness of treatments for this patient population.
Because patients with relapsed...
08/27/2020
First Report Managed Care
Podcasts
Discussing Effectiveness, Persistence Rates for Atopic Dermatitis Therapy
08/13/2020
Jonathan Silverberg, MD, PhD, MPH, associate professor of dermatology at The George Washington University School of Medicine and Health Sciences, Washington, DC, offers insight into his real-world data study in which he and his colleagues...
Jonathan Silverberg, MD, PhD, MPH, associate professor of dermatology at The George Washington University School of Medicine and Health Sciences, Washington, DC, offers insight into his real-world data study in which he and his colleagues...
Jonathan Silverberg, MD, PhD,...
08/13/2020
First Report Managed Care

Newsfeed

News
Added SGLT2 Inhibitor Therapy of Intermediate/Low Value in Heart Failure With Preserved Ejection Fraction 
03/29/2023
Jolynn Tumolo
Researchers investigated the lifetime cost effectiveness of standard therapy with vs without an SGLT2 inhibitor to reduce the risk of adverse outcomes in patients with heart failure.
Researchers investigated the lifetime cost effectiveness of standard therapy with vs without an SGLT2 inhibitor to reduce the risk of adverse outcomes in patients with heart failure.
Researchers investigated the...
03/29/2023
First Report Managed Care
News
Cost-Effectiveness of Implantable Loop Recorder Monitoring After Stroke in Line Wth Other Therapies
12/06/2020
For detecting occult atrial fibrillation in patients with cryptogenic stroke, 3-year implantable loop recorder monitoring has a cost per quality-adjusted life-year gained in the range of other publicly funded therapies
For detecting occult atrial fibrillation in patients with cryptogenic stroke, 3-year implantable loop recorder monitoring has a cost per quality-adjusted life-year gained in the range of other publicly funded therapies
For detecting occult atrial...
12/06/2020
First Report Managed Care
Conference Insider
Latanoprostene Bunod Proves Cost-Effective for Primary Open-Angle Glaucoma
11/20/2019
When compared to prostaglandin analogs (PGA), latanoprostene bunod appears to be cost-saving in the treatment of primary open-angle glaucoma, according to data presented at AMCP Nexus 2019. 
When compared to prostaglandin analogs (PGA), latanoprostene bunod appears to be cost-saving in the treatment of primary open-angle glaucoma, according to data presented at AMCP Nexus 2019. 
When compared to prostaglandin...
11/20/2019
First Report Managed Care
News
IMC Care Matches ICU Outcomes for Hypertensive Emergencies, Study Finds
05/04/2026
Rebecca Amrick
In a recent study, patients with hypertensive emergencies had similar outcomes in intermediate care (IMC) and intensive care unit (ICU) settings, suggesting IMC units may safely reduce ICU utilization without compromising care.
In a recent study, patients with hypertensive emergencies had similar outcomes in intermediate care (IMC) and intensive care unit (ICU) settings, suggesting IMC units may safely reduce ICU utilization without compromising care.
In a recent study, patients with...
05/04/2026
First Report Managed Care
News
Adjuvant Immunotherapy Costs Challenge Lung Cancer Affordability
05/04/2026
Hannah Musick
Adjuvant immunotherapies may improve lung cancer outcomes, but high costs and budget impact concerns highlight the need for biomarker-guided use, value-based pricing, and phased adoption.
Adjuvant immunotherapies may improve lung cancer outcomes, but high costs and budget impact concerns highlight the need for biomarker-guided use, value-based pricing, and phased adoption.
Adjuvant immunotherapies may...
05/04/2026
First Report Managed Care
News
Teclistamab Shows Comparable Efficacy but Lower Costs Than Elranatamab in RRMM Study
05/04/2026
Rebecca Amrick
With similar response rates but consistently lower costs, teclistamab may offer a more economically favorable option than elranatamab for patients with relapsed or refractory multiple myeloma (RRMM), according to a study published in the...
With similar response rates but consistently lower costs, teclistamab may offer a more economically favorable option than elranatamab for patients with relapsed or refractory multiple myeloma (RRMM), according to a study published in the...
With similar response rates but...
05/04/2026
First Report Managed Care
News
Glofitamab Emerges as an Accessible, High-Potential Alternative to CAR T Therapy in DLBCL
04/29/2026
Rebecca Amrick
Dr Tycel Phillips from Blood Cancers Today explains how the bispecific antibody glofitamab may offer a more accessible and potentially curative alternative to chimeric antigen receptor (CAR) T-cell therapy for patients with diffuse large...
Dr Tycel Phillips from Blood Cancers Today explains how the bispecific antibody glofitamab may offer a more accessible and potentially curative alternative to chimeric antigen receptor (CAR) T-cell therapy for patients with diffuse large...
Dr Tycel Phillips from Blood...
04/29/2026
First Report Managed Care
News
Hemodialysis Triggers Wide Epigenetic Changes in Patients With Chronic Kidney Disease
04/27/2026
Rebecca Amrick
A small-scale exploratory study analyzed the impact of hemodialysis on DNA methylation patterns and found inflammation to be linked a system-wide reaction.
A small-scale exploratory study analyzed the impact of hemodialysis on DNA methylation patterns and found inflammation to be linked a system-wide reaction.
A small-scale exploratory study...
04/27/2026
First Report Managed Care
News
Sequencing of Bispecific Antibodies May Influence Outcomes in R/R Follicular Lymphoma
04/24/2026
Rebecca Amrick
A real-world multicenter study suggests bispecific antibodies remain effective in relapsed or refractory follicular lymphoma (R/R FL), but treatment sequencing may impact progression-free survival.
A real-world multicenter study suggests bispecific antibodies remain effective in relapsed or refractory follicular lymphoma (R/R FL), but treatment sequencing may impact progression-free survival.
A real-world multicenter study...
04/24/2026
First Report Managed Care
News
Trump Administration Announces 17th Most-Favored-Nation Drug Pricing Agreement With Regeneron
04/23/2026
Danielle Sposato
The Trump Administration today announced a new agreement with pharmaceutical manufacturer Regeneron aimed at aligning US prescription drug prices with those paid in other developed nations under a most-favored-nation (MFN) pricing model.
The Trump Administration today announced a new agreement with pharmaceutical manufacturer Regeneron aimed at aligning US prescription drug prices with those paid in other developed nations under a most-favored-nation (MFN) pricing model.
The Trump Administration today...
04/23/2026
First Report Managed Care
News
Trump Administration Announces 17th Most-Favored-Nation Drug Pricing Agreement With Regeneron
04/23/2026
Danielle Sposato
The Trump Administration today announced a new agreement with pharmaceutical manufacturer Regeneron aimed at aligning US prescription drug prices with those paid in other developed nations under a most-favored-nation (MFN) pricing model.
The Trump Administration today announced a new agreement with pharmaceutical manufacturer Regeneron aimed at aligning US prescription drug prices with those paid in other developed nations under a most-favored-nation (MFN) pricing model.
The Trump Administration today...
04/23/2026
First Report Managed Care
News
Semaglutide Shows Health Benefits for CVD but Falls Short on Cost-Effectiveness at Current Drug Prices
04/23/2026
Rebecca Amrick
A simulation study found that semaglutide could deliver meaningful health benefits as a secondary prevention strategy for cardiovascular disease (CVD) but will only be cost-effective if current drug prices are reduced.
A simulation study found that semaglutide could deliver meaningful health benefits as a secondary prevention strategy for cardiovascular disease (CVD) but will only be cost-effective if current drug prices are reduced.
A simulation study found that...
04/23/2026
First Report Managed Care
Behind the Bill
DOJ Places FDA-Approved Marijuana Products in Schedule III
04/23/2026
Grace Taylor, MS, MA
The US Department of Justice (DOJ) has reclassified certain US Food and Drug Administration (FDA)-approved marijuana products as Schedule III substances, a shift that may expand research and influence future clinical and coverage decisions in...
The US Department of Justice (DOJ) has reclassified certain US Food and Drug Administration (FDA)-approved marijuana products as Schedule III substances, a shift that may expand research and influence future clinical and coverage decisions in...
The US Department of Justice...
04/23/2026
First Report Managed Care

Literature Review

Literature Review
Improved Therapy Options for Patients with Neuroendocrine Tumors
02/23/2019
Kara Rosania, MS
Neuroendocrine tumors (NETs) are thought to arise from cells throughout the diffuse endocrine system. According to a report published in JAMA Oncology, the incidence and prevalence of NETS are steadily rising, though for reasons not well...
Neuroendocrine tumors (NETs) are thought to arise from cells throughout the diffuse endocrine system. According to a report published in JAMA Oncology, the incidence and prevalence of NETS are steadily rising, though for reasons not well...
Neuroendocrine tumors (NETs) are...
02/23/2019
First Report Managed Care
Literature Review
Promising Outcomes for SER-109: A New Approach to Managing Recurrent CDI
10/23/2023
Danielle Sposato
Not only does SER-109 effectively treat CDI, but results show that it can even reduce recurrence. A major benefit when it comes to associated health care costs for patients.
Not only does SER-109 effectively treat CDI, but results show that it can even reduce recurrence. A major benefit when it comes to associated health care costs for patients.
Not only does SER-109...
10/23/2023
First Report Managed Care
Literature Review
Comparing IL-6 Inhibitors and Glucocorticoids in Treating PMR: SAPHYR Trial Results
10/16/2023
Danielle Sposato
The SAPHYR trial has provided researchers with valuable insights into alternative treatment options for PMR due to its larger patient population. The effectiveness of sarilumab and the achieved rates of remission offer promise for enhancing...
The SAPHYR trial has provided researchers with valuable insights into alternative treatment options for PMR due to its larger patient population. The effectiveness of sarilumab and the achieved rates of remission offer promise for enhancing...
The SAPHYR trial has provided...
10/16/2023
First Report Managed Care
Literature Review
A Look at the Impact, Prevalence of Demodex Blepharitis
12/06/2022
Edan Stanley
This article explores the incidence, prevalence, and management of Demodex Blepharitis.
This article explores the incidence, prevalence, and management of Demodex Blepharitis.
This article explores the...
12/06/2022
First Report Managed Care
Literature Review
Anti-CD38 Monoclonal Antibody for Multiple Myeloma: A Review of Clinical Trials
11/29/2022
Maria Asimopoulos
Several ongoing and upcoming clinical trials are testing the efficacy and safety of a monoclonal antibody in combination with other therapies for multiple myeloma.
Several ongoing and upcoming clinical trials are testing the efficacy and safety of a monoclonal antibody in combination with other therapies for multiple myeloma.
Several ongoing and upcoming...
11/29/2022
First Report Managed Care
Literature Review
Isatuximab Demonstrates Significant PFS Among Patients With Multiple Myeloma
09/23/2022
Edan Stanley
This literature review explores the latest progression-free survival data for a multiple myeloma therapy option.
This literature review explores the latest progression-free survival data for a multiple myeloma therapy option.
This literature review explores...
09/23/2022
First Report Managed Care
Literature Review
Bladder Cancers: What is Low-Grade Upper Tract Urothelial Carcinoma?
09/16/2022
Edan Stanley
This literature review explores key data related to the epidemiology, clinical presentation, and treatment considerations for patients with low-grade upper tract urothelial carcinoma.
This literature review explores key data related to the epidemiology, clinical presentation, and treatment considerations for patients with low-grade upper tract urothelial carcinoma.
This literature review explores...
09/16/2022
First Report Managed Care
Literature Review
Examining 177Lu-PSMA-617 as a Treatment for Metastatic Castration-resistant Prostate Cancer
09/16/2021
Jeff Craven
In this literature review, we explore the data from the phase 3 VISION trial recently presented at the 2021 virtual annual meeting of the American Society of Clinical Oncology and published in the New England Journal of Medicine, examining...
In this literature review, we explore the data from the phase 3 VISION trial recently presented at the 2021 virtual annual meeting of the American Society of Clinical Oncology and published in the New England Journal of Medicine, examining...
In this literature review, we...
09/16/2021
First Report Managed Care
Literature Review
Examining Benefits of Cannabidiol for Patients With Seizures
08/12/2021
Edan Stanley
For the purpose of this literature review, we examine the latest data presented at the American Academy of Neurology’s (AAN) 2021 Virtual Annual Meeting regarding the use of CBD for patients with seizure disorders including TSC.  
For the purpose of this literature review, we examine the latest data presented at the American Academy of Neurology’s (AAN) 2021 Virtual Annual Meeting regarding the use of CBD for patients with seizure disorders including TSC.  
For the purpose of this...
08/12/2021
First Report Managed Care
Literature Review
Examining Dry Eye Disease Flare Treatments
05/28/2021
Edan Stanley
With a newly proposed and easily applicable definition for dry eye disease, researchers believe the condition can be diagnosed with more consistency as well as inform future trials and research. 
With a newly proposed and easily applicable definition for dry eye disease, researchers believe the condition can be diagnosed with more consistency as well as inform future trials and research. 
With a newly proposed and easily...
05/28/2021
First Report Managed Care
Literature Review
Examining Lasmiditan for the Acute Treatment of Migraine Compared With Triptans
02/12/2021
Edan Stanley
Per the American Migraine foundation, oral and intranasal triptan therapy has proven consistently effective when used to treat migraine earlier in the attack; however, triptan therapy is not effective for all patients with migraine and cannot...
Per the American Migraine foundation, oral and intranasal triptan therapy has proven consistently effective when used to treat migraine earlier in the attack; however, triptan therapy is not effective for all patients with migraine and cannot...
Per the American Migraine...
02/12/2021
First Report Managed Care

Literature Review

Literature Review
Improved Therapy Options for Patients with Neuroendocrine Tumors
02/23/2019
Kara Rosania, MS
Neuroendocrine tumors (NETs) are thought to arise from cells throughout the diffuse endocrine system. According to a report published in JAMA Oncology, the incidence and prevalence of NETS are steadily rising, though for reasons not well...
Neuroendocrine tumors (NETs) are thought to arise from cells throughout the diffuse endocrine system. According to a report published in JAMA Oncology, the incidence and prevalence of NETS are steadily rising, though for reasons not well...
Neuroendocrine tumors (NETs) are...
02/23/2019
First Report Managed Care
Literature Review
Promising Outcomes for SER-109: A New Approach to Managing Recurrent CDI
10/23/2023
Danielle Sposato
Not only does SER-109 effectively treat CDI, but results show that it can even reduce recurrence. A major benefit when it comes to associated health care costs for patients.
Not only does SER-109 effectively treat CDI, but results show that it can even reduce recurrence. A major benefit when it comes to associated health care costs for patients.
Not only does SER-109...
10/23/2023
First Report Managed Care
Literature Review
Comparing IL-6 Inhibitors and Glucocorticoids in Treating PMR: SAPHYR Trial Results
10/16/2023
Danielle Sposato
The SAPHYR trial has provided researchers with valuable insights into alternative treatment options for PMR due to its larger patient population. The effectiveness of sarilumab and the achieved rates of remission offer promise for enhancing...
The SAPHYR trial has provided researchers with valuable insights into alternative treatment options for PMR due to its larger patient population. The effectiveness of sarilumab and the achieved rates of remission offer promise for enhancing...
The SAPHYR trial has provided...
10/16/2023
First Report Managed Care
Literature Review
A Look at the Impact, Prevalence of Demodex Blepharitis
12/06/2022
Edan Stanley
This article explores the incidence, prevalence, and management of Demodex Blepharitis.
This article explores the incidence, prevalence, and management of Demodex Blepharitis.
This article explores the...
12/06/2022
First Report Managed Care
Literature Review
Anti-CD38 Monoclonal Antibody for Multiple Myeloma: A Review of Clinical Trials
11/29/2022
Maria Asimopoulos
Several ongoing and upcoming clinical trials are testing the efficacy and safety of a monoclonal antibody in combination with other therapies for multiple myeloma.
Several ongoing and upcoming clinical trials are testing the efficacy and safety of a monoclonal antibody in combination with other therapies for multiple myeloma.
Several ongoing and upcoming...
11/29/2022
First Report Managed Care
Literature Review
Isatuximab Demonstrates Significant PFS Among Patients With Multiple Myeloma
09/23/2022
Edan Stanley
This literature review explores the latest progression-free survival data for a multiple myeloma therapy option.
This literature review explores the latest progression-free survival data for a multiple myeloma therapy option.
This literature review explores...
09/23/2022
First Report Managed Care
Literature Review
Bladder Cancers: What is Low-Grade Upper Tract Urothelial Carcinoma?
09/16/2022
Edan Stanley
This literature review explores key data related to the epidemiology, clinical presentation, and treatment considerations for patients with low-grade upper tract urothelial carcinoma.
This literature review explores key data related to the epidemiology, clinical presentation, and treatment considerations for patients with low-grade upper tract urothelial carcinoma.
This literature review explores...
09/16/2022
First Report Managed Care
Literature Review
Examining 177Lu-PSMA-617 as a Treatment for Metastatic Castration-resistant Prostate Cancer
09/16/2021
Jeff Craven
In this literature review, we explore the data from the phase 3 VISION trial recently presented at the 2021 virtual annual meeting of the American Society of Clinical Oncology and published in the New England Journal of Medicine, examining...
In this literature review, we explore the data from the phase 3 VISION trial recently presented at the 2021 virtual annual meeting of the American Society of Clinical Oncology and published in the New England Journal of Medicine, examining...
In this literature review, we...
09/16/2021
First Report Managed Care
Literature Review
Examining Benefits of Cannabidiol for Patients With Seizures
08/12/2021
Edan Stanley
For the purpose of this literature review, we examine the latest data presented at the American Academy of Neurology’s (AAN) 2021 Virtual Annual Meeting regarding the use of CBD for patients with seizure disorders including TSC.  
For the purpose of this literature review, we examine the latest data presented at the American Academy of Neurology’s (AAN) 2021 Virtual Annual Meeting regarding the use of CBD for patients with seizure disorders including TSC.  
For the purpose of this...
08/12/2021
First Report Managed Care
Literature Review
Examining Dry Eye Disease Flare Treatments
05/28/2021
Edan Stanley
With a newly proposed and easily applicable definition for dry eye disease, researchers believe the condition can be diagnosed with more consistency as well as inform future trials and research. 
With a newly proposed and easily applicable definition for dry eye disease, researchers believe the condition can be diagnosed with more consistency as well as inform future trials and research. 
With a newly proposed and easily...
05/28/2021
First Report Managed Care
Literature Review
Examining Lasmiditan for the Acute Treatment of Migraine Compared With Triptans
02/12/2021
Edan Stanley
Per the American Migraine foundation, oral and intranasal triptan therapy has proven consistently effective when used to treat migraine earlier in the attack; however, triptan therapy is not effective for all patients with migraine and cannot...
Per the American Migraine foundation, oral and intranasal triptan therapy has proven consistently effective when used to treat migraine earlier in the attack; however, triptan therapy is not effective for all patients with migraine and cannot...
Per the American Migraine...
02/12/2021
First Report Managed Care

First Report

First Report
HEOR First Report: A Deeper Look at the Benefits of Hemlibra
08/31/2020
Edan Stanley
Karen Powell, PharmD, MS, Pharmacy Solutions Coordinator, Conduent, discusses a recent study in which she and her colleagues measured the cost effectiveness and utilizations rates associated with emicizumab-kxwh treatment for patients with...
Karen Powell, PharmD, MS, Pharmacy Solutions Coordinator, Conduent, discusses a recent study in which she and her colleagues measured the cost effectiveness and utilizations rates associated with emicizumab-kxwh treatment for patients with...
Karen Powell, PharmD, MS,...
08/31/2020
First Report Managed Care
First Report
Vibegron Proves Effective as Oral Therapy for Patients With Overactive Bladder
04/12/2021
Edan Stanley
While OAB is not associated with high mortality rates, its effects on quality of life and overall burden can be stressful to patients and diagnosis/treatment is often delayed due to patients’ lack of understanding of available treatments.
While OAB is not associated with high mortality rates, its effects on quality of life and overall burden can be stressful to patients and diagnosis/treatment is often delayed due to patients’ lack of understanding of available treatments.
While OAB is not associated with...
04/12/2021
First Report Managed Care
First Report
HEOR First Report: A Deeper Look at the Benefits of Hemlibra
08/31/2020
Edan Stanley
Karen Powell, PharmD, MS, Pharmacy Solutions Coordinator, Conduent, discusses a recent study in which she and her colleagues measured the cost effectiveness and utilizations rates associated with emicizumab-kxwh treatment for patients with...
Karen Powell, PharmD, MS, Pharmacy Solutions Coordinator, Conduent, discusses a recent study in which she and her colleagues measured the cost effectiveness and utilizations rates associated with emicizumab-kxwh treatment for patients with...
Karen Powell, PharmD, MS,...
08/31/2020
First Report Managed Care
First Report
Decreased Medication, Utilization Costs Identified With Emicizumab-kxwh Therapy for Hemophilia
08/31/2020
Edan Stanley
Emicizumab-kxwh, which was approved by the FDA in November 2017 to prevent or reduce the frequency of bleeding episodes in patients with hemophilia (HEM) A and FVIII inhibitors, was found to be associated with decreased medication and...
Emicizumab-kxwh, which was approved by the FDA in November 2017 to prevent or reduce the frequency of bleeding episodes in patients with hemophilia (HEM) A and FVIII inhibitors, was found to be associated with decreased medication and...
Emicizumab-kxwh, which was...
08/31/2020
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use